Please try another search
For the nine months ended 31 December 2020, UrovantSciences Ltd revenues was not reported. Net loss increased18% to $112.4M. Higher net loss reflects General andadministrative - Balancing increase from $18.2M to $53.3M(expense), Interest expense, net increase of 81% to $4.5M(expense), Other income (expense) increase of 7% to $155K(expense). Basic Earnings per Share excluding ExtraordinaryItems decreased from -$3.14 to -$3.58.
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -45.58 | -33.47 | -28.84 | -50.33 |
Net Income | -46.8 | -35.16 | -30.49 | -51.26 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 108.89 | 91.46 | 78.14 | 63.3 |
Total Liabilities | 254.5 | 204.51 | 163.07 | 121.3 |
Total Equity | -145.62 | -113.05 | -84.94 | -58.01 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 0 Months |
Cash From Operating Activities | -110.27 | -63.44 | -30.8 | -102.08 |
Cash From Investing Activities | -1.33 | -0.45 | -0.1 | -0.77 |
Cash From Financing Activities | 133.06 | 88.46 | 42.54 | 68.94 |
Net Change in Cash | 21.46 | 24.57 | 11.63 | -33.92 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review